Reuters logo
BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication
September 21, 2017 / 10:24 AM / 3 months ago

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

Sept 21 (Reuters) - Biocryst Pharmaceuticals Inc

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

* Biocryst Pharmaceuticals Inc - ‍FDA has approved a supplemental new drug application for Rapivab​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below